Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03168308 · ClinicalTrials.gov registry record · Phase 4
Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients
A Phase 4 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 92
- Enrollment target
NCT03168308 is a Phase 4 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 92 participants.
The verdict
NCT03168308, a Phase 4 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 92 participants
- Enrollment target
Study Summary
This prospective, randomized, double blinded study is intended to enroll a total of 92 patients undergoing thoracic surgery with general endotracheal anesthesia at Parkland Hospital. Patients will be randomized to receive either neostigmine or sugammadex for reversal of neuromuscular blockade. Merck, Inc. will supply the sugammadex through an agreement with Parkland Investigational Drug Services. Neostigmine is readily available for anesthesiologists to use and is the current standard of care for reversal of neuromuscular blockade. A standardized anesthetic protocol that is usual and customary for the type of operation the patient is having will be provided to the anesthesia teams of enrolled subjects. The remainder of the anesthetic care of the subject will not deviate from the standard of care. The surgeon, anesthesia team, postoperative recovery nurse, and research assistant will be blinded as to which reversal drug the patient receives. The only individual that will know to which drug the patient has been randomized will be the pharmacist who draws up the medication(s). A blinded research assistant will record postoperative outcomes and the patient will be followed 90 minutes postoperatively for any adverse events.
Interventions
- DRUG Sugammadex
- DRUG Neostigmine w/ Glycopyrrolate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2017-09-26 |
| Est. Completion | 2019-09-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03168308
The ClinicalTrials.gov registry entry for NCT03168308 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sugammadex is the first listed.
NCT03168308 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03168308 about?
NCT03168308 is a clinical study titled "Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients". This prospective, randomized, double blinded study is intended to enroll a total of 92 patients undergoing thoracic surgery with general endotracheal anesthesia at Parkland Hospital. Patients will be randomized to receive either neostigmine or sugammadex for reversal of neuromuscular blockade. Merck...
What is the current status of trial NCT03168308?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 92 participants. The study started on 2017-09-26. Estimated completion is 2019-09-30.
What interventions are being tested in trial NCT03168308?
The interventions under investigation include: Sugammadex (DRUG), Neostigmine w/ Glycopyrrolate (DRUG).
Who is sponsoring clinical trial NCT03168308?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.